Abstract:Objective To evaluate the efficacy of pegylated interferon (PEG-IFN-ɑ-2a or PEG-IFN-ɑ-2b) and common interferon in the treatment of HBeAg positive chronic hepatitis B. Methods Randomized controlled trials (RCTs) about the efficacy comparison between pegylated interferon (PEG-IFN-ɑ-2a or PEG-IFN-ɑ-2b) and common in-terferon for the treatment of HBeAg positive chronic hepatitis B before July 1st , 2016 were searched from Medline, Em-base, EBSCO, Chinese Biomedical Literature Database (CBM), VIP, CNKI and Wanfang database. The references of the obtained literatures were also traced. Mate-analysis was performed by using RevMan 5.2 software after two researchers screened literature independently, extracted data and assessed the risk of bias. Results Thirteen RCTs (n=1263) were involved, including 616 cases in Pegylated interferon group and 647 cases in common interferon group. The results of meta-analysis showed that at 24 week and 48 week, the ALT normalization, HBV-DNA negative conversion rate and HBeAg negative conversion rate in Pegylated interferon group were significantly higher than those in common interfer-on group (P<0.05). At 12 week, HBV-DNA negative conversion rate in Pegylated interferon group was higher than that in common interferon group (Z=2.19,P=0.03), but there were no statistical differences in ALT normalization and HBeAg negative conversion rate between Pegylated interferon group and common interferon group (P>0.05). At 12 week and 24 week, there was no statistical difference in the HBsAg negative conversion rate between the two groups (P>0.05), but at 48 week, HBsAg negative conversion rate in Pegylated interferon group was higher than that in common in-terferon group (Z=2.34, P=0.02). At 12 week and 48 week, there was no statistical difference in the HBeAg seroconver-sion rate between Pegylated interferon group and common interferon group (P>0.05), however, that in the Pegylated in-terferon group was higher than common interferon group at 24 week (Z=2.90, P=0.004). Conclusion After the treat-ment for 24 weeks and 48 weeks, Pegylated interferon (PEG-IFN-ɑ-2a or PEG-IFN-ɑ-2b) was superior to common in-terferon in ALT normalization, HBV-DNA negative conversion rate, HBeAg negative conversion rate. At 48 week, only HBsAg negative conversion rate in Pegylated interferon group was higher than that in common interferon group, and at 24 week, only HBeAg seroconversion rate in Pegylated interferon group was higher than common interferon. Due to the quantity and quality limitations of included studies, more high quality studies are needed to verify the above conclusions.

Effect of Conventional Interferon‐α in Patients with HBeAg‐positive Chronic Hepatitis B: a Systematic Review and Meta‐analysis

Long-Term Effect of Interferon Treatment on the Progression of Chronic Hepatitis B: Bayesian Meta-Analysis and Meta-Regression

Clinical Study of the Efficacy of Interferon-Α Therapy for HBeAg-negative Chronic Hepatitis B Patients

Effects Of Interferon Treatment On Development And Progression Of Hepatocellular Carcinoma In Patients With Chronic Virus Infection: A Meta-Analysis Of Randomized Controlled Trials

Clinic Study of Long-term Follow-up of Chronic Hepatitis B Patients Treated with Interferon Alfa

[Early Indexes to Predict the Therapeutic Effect of Interferon on Chronic Hepatitis B].

A Clinical Study of the Efficacy of Α-Interferon Therapy for HBeAg Negative Chronic Hepatitis B

Interferon‐alpha Plus Adefovir Combination Therapy Versus Interferon‐alpha Monotherapy for Chronic Hepatitis B Treatment: A Meta‐analysis

Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

Concurrence and Impact of Hepatic Steatosis on Chronic Hepatitis B Patients: a Systematic Review and Meta-Analysis

A Potential Functional Cure In Chinese Hbeag-Negative Chronic Hepatitis B Patients Treated With Peg-Interferon Alpha-2a

Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis

Efficacy and safety of interferon based antiviral therapy for children with hepatitis B: a meta-analysis

Effect of interferon therapy on quality of life in patients with chronic hepatitis B

Effects of Tenofovir Combined with Recombinant Human Interferon Α-2B on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis

Meta analysis of efficacy of pegylated interferon versus common interferon in the treatment of HBeAg positive chronic hepatitis B

Interferon: a Sharp Sword to Overcome HCV or HBV-related Liver Diseases?

Interferon and interferon-stimulated genes in HBV treatment

Advance in Molecular Mechanism of Interferon to Treat Chronic Hepatitis B